Non-Hodgkin Lymphoma

Combining the CD30-directed antibody-drug conjugate brentuximab vedotin with R-CHOP yielded objective responses in 80% of patients with advanced DLBCL in a phase II trial.

John P. Leonard, MD, discusses the phase III SELENE and AUGMENT trials, along with smaller investigations, which hope to uncover more efficacious treatments for patients with NHL.

OncLive spoke with Bruce D. Cheson, MD, to gain a deeper understanding about the significance of the GADOLIN study results.

John P. Leonard, MD, medical oncology, NewYork-Presbyterian Hospital/Weill Cornell Medical Center, discusses an ongoing study examining the use of lenalidomide combined with rituximab in patients with recurrent follicular lymphoma.

Martin Barrett, PhD, Clinical Scientist at Hoffmann-La Roche, discusses a study which compared intravenous (IV) rituximab to subcutaneous rituximab in non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL).

Infusions of CTL019 achieved durable responses and showed an acceptable safety profile in heavily pretreated patients with CD19-positive non-Hodgkin lymphoma.

Carolina Moreno Atanasio, MD, University of Barcelona, discusses an ongoing phase III study comparing ibrutinib and obinutuzumab with chlorambucil and obinutuzumab in treatment-naïve patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

A chemotherapy-free combination of the anti-CD20 antibody ublituximab, ibrutinib, and the PI3K delta inhibitor TGR-1202 demonstrated robust clinical activity in patients with relapsed/refractory chronic lymphocytic leukemia or B-cell non-Hodgkin lymphoma.

Patients with relapsed indolent non-Hodgkin lymphoma experienced a doubling of progression-free survival when treated with a combination of the anti-CD20 agent obinutuzumab and bendamustine.

In an interview with OncLive, John Radford, MD, discusses the impact of novel agents in non-Hodgkin lymphoma and what continued research is necessary to overcome treatment challenges.

Although CLL is the most common chronic leukemia, there remains no single agreed-upon standard of care for first-line treatment.

Low vitamin D levels prior to treatment may be linked to risk of relapse or death for patients with follicular lymphoma.

M. Yair Levy, MD, discussed the impact of non-chemotherapeutic agents on the treatment of patients with NHL in an interview with OncLive.

Randy Gascoyne, MD, research director, Centre for Lymphoid Cancers at the BC Cancer Agency, discusses the growth of predictive biomarker research in follicular lymphoma and other malignancies.